Correlation Between Transcode Therapeutics and Protalix Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Transcode Therapeutics and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Transcode Therapeutics and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Transcode Therapeutics and Protalix Biotherapeutics, you can compare the effects of market volatilities on Transcode Therapeutics and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Transcode Therapeutics with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Transcode Therapeutics and Protalix Biotherapeutics.
Diversification Opportunities for Transcode Therapeutics and Protalix Biotherapeutics
-0.23 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Transcode and Protalix is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding Transcode Therapeutics and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Transcode Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Transcode Therapeutics are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Transcode Therapeutics i.e., Transcode Therapeutics and Protalix Biotherapeutics go up and down completely randomly.
Pair Corralation between Transcode Therapeutics and Protalix Biotherapeutics
Given the investment horizon of 90 days Transcode Therapeutics is expected to under-perform the Protalix Biotherapeutics. In addition to that, Transcode Therapeutics is 1.07 times more volatile than Protalix Biotherapeutics. It trades about -0.18 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.33 per unit of volatility. If you would invest 117.00 in Protalix Biotherapeutics on September 1, 2024 and sell it today you would earn a total of 55.00 from holding Protalix Biotherapeutics or generate 47.01% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Transcode Therapeutics vs. Protalix Biotherapeutics
Performance |
| Timeline |
| Transcode Therapeutics |
| Protalix Biotherapeutics |
Transcode Therapeutics and Protalix Biotherapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Transcode Therapeutics and Protalix Biotherapeutics
The main advantage of trading using opposite Transcode Therapeutics and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Transcode Therapeutics position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.| Transcode Therapeutics vs. Tff Pharmaceuticals | Transcode Therapeutics vs. Eliem Therapeutics | Transcode Therapeutics vs. Inhibrx | Transcode Therapeutics vs. Enliven Therapeutics |
| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |